Initial Results of a Lung Cancer Screening Demonstration Project: A Local Program Evaluation
Results, lessons, and challenges of a local lung cancer screening program within a national demonstration project.
Physician Practice Variation Under Orthopedic Bundled Payment
This study demonstrates that variation reduction is an important, but not requisite, component of organizational success under orthopedic bundled payment.
Prevalence and Predictors of Hypoglycemia in South Korea
The prevalence and predictors of hypoglycemia in South Korean patients with type 2 diabetes were evaluated using a nationwide healthcare database.
A Longitudinal Examination of the Asthma Medication Ratio in Children
This longitudinal examination of the asthma medication ratio in a national sample of children has determined the predictive accuracy of a rolling 3-month ratio.
Cost Sharing for Antiepileptic Drugs: Medication Utilization and Health Plan Costs
Increased out-of-pocket costs for antiepileptic drugs were associated with decreased adherence, higher healthcare utilization, and higher spending among US commercial health plan beneficiaries with epilepsy.
Satisfaction With Care After Reducing Opioids for Chronic Pain
There is no significant association between unfavorable patient satisfaction and opioid reductions for chronic pain, but encounters with unestablished providers may slightly impair satisfaction when reducing opioids.
Assessing Markers From Ambulatory Laboratory Tests for Predicting High-Risk Patients
An evaluation of the added value of risk markers derived from ambulatory laboratory tests in the prediction of healthcare costs and identification of high-risk patients.
Identifying Children at Risk of Asthma Exacerbations: Beyond HEDIS
June 7th 2018Analysis of insurance claims reveals that criteria other than the Healthcare Effectiveness Data and Information Set (HEDIS) persistent asthma definition can identify more at-risk patients with reasonable loss of specificity.
Placement of Selected New FDA-Approved Drugs in Medicare Part D Formularies, 2009-2013
There is significant heterogeneity in formulary placement and restrictions on new drug approvals in the Part D marketplace.